Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | IKBKB | O14920 | 1/20 | 0.32 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | APAF1 | O14727 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | F2 | P00734 | 1/20 | 0.32 |
| ▸ | PLAU | P00749 | 1/20 | 0.32 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL376224 | 0.79 | L3MBTL1 (0.38) | ALDH1A1ATMNPSR1L3MBTL1POLB | |
| SCHEMBL27881026 | 0.78 | L3MBTL1 (0.33) | ALDH1A1L3MBTL1POLBKDM4ENPC1 | |
| Hydrochloric Acid SCHEMBL11562510 | 0.77 | L3MBTL1 (0.33) | ALDH1A1L3MBTL1POLBKDM4E | |
| SCHEMBL22749935 | 0.75 | KDM4E (0.43) | ALDH1A1IKBKBKMT2AKDM4ENPC1 | |
| SCHEMBL15512886 | 0.75 | GAA (0.35) | ALDH1A1IKBKBIKBKEL3MBTL1KMT2A | |
| SCHEMBL18059711 | 0.75 | ALDH1A1 (0.33) | ALDH1A1NPSR1HTTKMT2AKDM4E | |
| SCHEMBL481939 | 0.74 | ROCK2 (0.34) | ATMHTTL3MBTL1KDM4EELANE | |
| Hydrochloric Acid SCHEMBL11558888 | 0.73 | MEN1 (0.33) | ALDH1A1HTTL3MBTL1POLBKMT2A | |
| SCHEMBL29223388 | 0.72 | KDM4E (0.33) | L3MBTL1KDM4E | |
| SCHEMBL21808338 | 0.71 | EPHX2 (0.57) | ALDH1A1ATMHTTL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150327-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2024-05-09 | — | — | US | disclosed |
| US-11905275-B2 | Bipyrazole derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2024-02-20 | — | — | US | disclosed |
| EP-4275756-A2 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | Incyte Holdings Corporation (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3786162-B1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | INCYTE HOLDINGS CORP (US) | 2023-08-09 | — | — | EP | disclosed |
| US-20230159501-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-11591318-B2 | Bipyrazole derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2023-02-28 | — | — | US | disclosed |
| US-20210238168-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | INCYTE CORPORATION | 2021-08-05 | — | — | US | disclosed |
| US-11001571-B2 | Bipyrazole derivatives as JAK inhibitors | INCYTE CORPORATION (US) | 2021-05-11 | — | — | US | disclosed |
| EP-3786162-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | Incyte Corporation (US) | 2021-03-03 | — | — | EP | disclosed |
| EP-3527263-B1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | INCYTE CORP (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | SIGNAL PHARMACEUTICALS, LLC | 2011-10-06 | — | — | US | disclosed |
| US-7981893-B2 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC (US) | 2011-07-19 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC (US) | 2011-06-16 | — | — | US | disclosed |
| WO-2010046780-A2 | ANTI VIRAL COMPOUNDS | INSTITUT PASTEUR KOREA (KR) | 2010-04-29 | — | — | WO | disclosed |
| WO-2010016005-A1 | 6 SUBSTITUTED 2-HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | PFIZER INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| EP-2090577-A2 | Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors | Signal Pharmaceuticals LLC (US) | 2009-08-19 | — | — | EP | disclosed |
| EP-2078016-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | Signal Pharmaceuticals LLC (US) | 2009-07-15 | — | — | EP | disclosed |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | SIGNAL PHARMACEUTICALS, LLC | 2009-01-22 | — | — | US | disclosed |
| WO-2008051493-A2 | HETEROARYL COMPOUNDS, COMPOSITIONS THEREOF, AND THEIR USE AS PROTEIN KINASE INHIBITORS | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905275-B2 | Bipyrazole derivatives as JAK inhibitors | JAK1, JAK2, JAK3 | ALDH1A1 2504/4885ATM 1718/4885NPSR1 4510/4885 |
| US-11591318-B2 | Bipyrazole derivatives as JAK inhibitors | JAK1, JAK2, JAK3 | ALDH1A1 2504/4885ATM 1718/4885NPSR1 4510/4885 |
| US-20210238168-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | ALDH1A1 2504/4885ATM 1718/4885NPSR1 4510/4885 |
| US-11001571-B2 | Bipyrazole derivatives as JAK inhibitors | JAK1, JAK2, JAK3 | ALDH1A1 2504/4885ATM 1718/4885NPSR1 4510/4885 |
| US-20110245245-A1 | METHODS OF TREATMENT COMPRISING THE ADMINISTRATION OF HETEROARYL COMPOUNDS | JAK2, GLS2, NFKBIA | ALDH1A1 2178/4885ATM 134/4885NPSR1 3371/4885 |
| US-20240150327-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | ALDH1A1 2504/4885ATM 1718/4885NPSR1 4510/4885 |
| US-20230159501-A1 | BIPYRAZOLE DERIVATIVES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | ALDH1A1 2504/4885ATM 1718/4885NPSR1 4510/4885 |
| US-20110144084-A1 | 6 SUBSTITUTED 2- HETEROCYCLYLAMINO PYRAZINE COMPOUNDS AS CHK-1 INHIBITORS | CHKA, CSNK1A1, CHKB | ALDH1A1 2651/4885ATM 1181/4885NPSR1 4242/4885 |
| US-20090023724-A1 | Heteroaryl compounds, compositions thereof, and methods of treatment therewith | JAK2, PHKG1, PHKG2 | ALDH1A1 1934/4885ATM 122/4885NPSR1 3921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.